Infigratinib for children with hypochondroplasia
Treatments studied
Part of Bones, joints & muscles, Genetic & congenital, Hormones & metabolism, Skin clinical trials.
This study tests an oral medication called infigratinib in children with hypochondroplasia, a form of short stature. It aims to see if the drug can help improve growth and is for children who are still growing.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Diagnosis of hypochondroplasia confirmed by genetic testing
- Able to swallow pills
- Must have been in a previous observation study for at least 26 weeks
- Able to stand without help and walk
- No other treatments for short stature or growth in the past
- No history of cancer, limb-lengthening surgery, or certain eye conditions
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study is for children with hypochondroplasia who already completed the ACCEL 2/3 trial. It tests the long-term safety and effects of the study drug infigratinib, and gives continued access to the treatment.
This study is for children with hypochondroplasia, a condition that causes short stature. It will look at how the condition changes over time and aims to better understand it, with the goal of finding new treatments.
This study tests a daily injection called vosoritide to see if it helps children with hypochondroplasia grow taller. It is for babies and toddlers up to 35 months old who are shorter than average for their age.
This study observes children with hypochondroplasia to learn more about the condition. It does not involve any treatment—just monitoring and data collection to help future research.
this study is a long-term extension of the main study for the drug which from Bio? bi? whatever? in the name? by?...????
This trial tests an oral medication called infigratinib to see if it can help young children with achondroplasia. It is for children under 3 years old who have a confirmed genetic diagnosis.
Hear when a new Hypochondroplasia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.